US 12,280,083 B2
Extracts of Moricandia for the use thereof in the prevention and treatment of metabolic diseases
Basma Abed, Ghomrassen Tataouine (TN); and Corinne Leloup, Messigny et Vantoux (FR)
Assigned to UNIVERSITÉ DE BOURGOGNE, Dijon (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris (FR); INSTITUT NATIONAL DE LA RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, Paris (FR); and UNIVERSITÉ DE MONASTIR, Monastir (TN)
Appl. No. 17/272,739
Filed by UNIVERSITÉ DE BOURGOGNE, Dijon (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris (FR); INSTITUT NATIONAL DE LA RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, Paris (FR); and UNIVERSITÉ DE MONASTIR, Monastir (TN)
PCT Filed Sep. 10, 2019, PCT No. PCT/FR2019/052092
§ 371(c)(1), (2) Date Mar. 2, 2021,
PCT Pub. No. WO2020/053519, PCT Pub. Date Mar. 19, 2020.
Claims priority of application No. 1858094 (FR), filed on Sep. 10, 2018.
Prior Publication US 2021/0346449 A1, Nov. 11, 2021
Int. Cl. A61K 36/31 (2006.01); A23L 33/105 (2016.01); A23L 33/18 (2016.01); A61K 36/481 (2006.01); A61P 3/04 (2006.01); A61P 3/10 (2006.01); A61P 5/50 (2006.01)
CPC A61K 36/31 (2013.01) [A23L 33/18 (2016.08); A61K 36/481 (2013.01); A61P 3/10 (2018.01)] 15 Claims
OG exemplary drawing
 
1. A method of treating a metabolic disease selected from the group consisting of insulin resistance or deficiency, glucose intolerance, hyperglycemia, and obesity, in a subject having type 2 diabetes, comprising administering to said subject a composition comprising an effective amount of an extract of Moricandia arvensis.